Brainstorm Cell Therapeutics Inc. (BCLI) Income Statement
BCLI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBCLI revenue and net income
Where BCLI's revenue goes
2025Each bar shows an amount and its share of revenue. BCLI kept −1,466.1% of revenue as net income.
BCLI profit margins
BCLI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −17.2% | — | — | — |
| Operating income | — | — | — | — |
| Net income | −188.7% | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BCLI quarterly EPS vs estimates
Brainstorm Cell Therapeutics beat the analyst EPS estimate in 5 of the last 7 quarters.
BCLI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $703,000 | $849,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $240,000 | $265,000 | $285,000 | $260,000 | $219,000 | $366,000 | $110,000 | $85,000 | $77,000 |
| Gross profit | — | −$240,000 | −$265,000 | −$285,000 | −$260,000 | −$219,000 | −$732,000 | −$110,000 | −$85,000 | −$77,000 |
| Research & development | $4.2M | $4.4M | $10.5M | $14.0M | $15.2M | $22.3M | $17.2M | $8.3M | $977,000 | $2.2M |
| Sales, general & admin | $5.8M | $7.0M | $10.7M | $10.9M | $9.3M | $9.4M | $5.8M | $5.8M | $4.0M | $2.8M |
| Total operating expenses | $10.0M | $11.7M | $21.2M | $24.8M | $24.5M | $31.7M | $23.0M | $14.1M | $5.0M | $5.1M |
| Operating income | −$10.0M | −$11.7M | −$21.4M | −$24.8M | −$24.5M | −$31.7M | −$23.0M | −$14.1M | −$5.0M | −$5.1M |
| Interest income | — | — | — | $545,000 | $82,000 | — | $252,000 | $115,000 | $47,000 | $101,000 |
| Interest expense | — | $77,000 | — | $545,000 | $82,000 | $127,000 | $252,000 | $115,000 | $47,000 | $101,000 |
| Income before taxes | −$10.3M | $11.6M | −$17.2M | −$24.3M | −$24.5M | −$31.8M | −$23.3M | −$13.9M | −$5.0M | −$5.0M |
| Income taxes | — | $11.6M | — | −$545,000 | −$82,000 | $127,000 | $252,000 | −$115,000 | −$47,000 | −$101,000 |
| Net income | −$10.3M | $11.6M | −$17.2M | −$23.7M | −$24.5M | −$31.8M | −$23.3M | −$13.9M | −$5.0M | −$5.0M |
| EBITDA | −$9.8M | −$11.3M | −$16.9M | −$24.5M | −$24.3M | −$31.5M | −$23.1M | −$13.8M | −$4.9M | −$4.9M |
| EPS (diluted) | −$1.11 | −$3.12 | −$7.64 | −$8.08 | −$7.82 | −$12.70 | −$15.90 | −$6.72 | −$1.11 | −$4.20 |
| Gross margin | — | −28.3% | — | — | — | — | — | — | — | — |
| Operating margin | −1,415.8% | −1,377.3% | — | — | — | — | — | — | — | — |
| Net margin | −1,466.1% | 1,369.0% | — | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $178,000 | $703,000 | $0 | $0 | $0 | $849,000 | $0 | $365,000 | $343,000 | $0 | $154,000 |
| Cost of revenue | $46,000 | $37,000 | $48,000 | — | — | $52,000 | $53,000 | $59,000 | $64,000 | $64,000 | $65,000 | $67,000 |
| Gross profit | −$46,000 | −$37,000 | −$48,000 | — | — | −$52,000 | −$53,000 | −$59,000 | −$64,000 | −$64,000 | −$65,000 | $87,000 |
| Research & development | $917,000 | $725,000 | $3.3M | $899,000 | $1.1M | $1.3M | $1.7M | $1.0M | $922,000 | $897,000 | $3.3M | $2.8M |
| Sales, general & admin | $2.6M | $1.3M | $4.4M | $1.1M | $1.5M | $1.8M | $1.5M | $2.0M | $2.1M | $1.5M | $2.7M | $2.7M |
| Total operating expenses | $3.6M | $2.0M | $2.2M | $2.0M | $2.6M | $3.1M | $3.2M | $3.0M | $3.0M | $2.5M | $6.0M | $5.4M |
| Operating income | −$3.6M | −$2.0M | −$2.2M | −$2.0M | −$2.6M | −$3.1M | −$3.2M | −$3.0M | −$3.0M | −$2.5M | −$6.0M | −$5.4M |
| Interest income | — | — | — | — | — | $46,000 | — | — | $30,000 | $13,000 | — | $120,000 |
| Interest expense | $242,000 | $81,000 | $330,000 | — | $330,000 | — | $66,000 | $54,000 | — | $92,000 | $121,000 | $120,000 |
| Income before taxes | −$3.9M | −$2.1M | −$2.4M | −$2.1M | −$2.9M | −$2.9M | −$3.0M | −$2.7M | −$2.5M | −$3.4M | −$1.2M | −$5.3M |
| Income taxes | — | — | — | — | — | — | — | — | — | $20,724 | −$4.9M | −$55,085 |
| Net income | −$3.9M | −$2.1M | −$2.4M | −$2.1M | −$2.9M | −$2.9M | −$3.0M | −$2.7M | −$2.5M | −$3.4M | −$1.2M | −$5.3M |
| EBITDA | −$3.6M | −$2.0M | −$2.2M | −$2.0M | −$2.5M | −$3.0M | −$3.1M | −$3.0M | −$2.9M | −$2.4M | −$6.0M | −$5.4M |
| EPS (diluted) | −$0.35 | −$0.19 | −$0.13 | −$0.19 | −$0.34 | −$0.45 | −$0.51 | −$0.51 | −$0.60 | −$1.50 | −$2.09 | −$1.95 |
| Gross margin | — | −20.8% | −6.8% | — | — | — | −6.2% | — | −17.5% | −18.7% | — | 56.5% |
| Operating margin | — | −1,149.4% | −319.2% | — | — | — | −375.6% | — | −817.0% | −721.3% | — | −3,538.3% |
| Net margin | — | −1,194.9% | −346.2% | — | — | — | −350.2% | — | −696.2% | −991.5% | — | −3,460.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BCLI's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BCLI financial results
In fiscal year 2025 (ended December 31, 2025), Brainstorm Cell Therapeutics reported revenue of $0.7 million, down 17.2% from the year before. It had a net loss of $10.3 million, a net profit margin of −1,466.1%. Diluted earnings per share came to −$1.11.
See the BCLI stock overview for the latest quote and news, or the BCLI chart for price history and technical indicators.
BCLI income statement FAQ
What is Brainstorm Cell Therapeutics's annual revenue?
Brainstorm Cell Therapeutics reported total revenue of $0.7 million for fiscal year 2025, which ended on December 31, 2025. That was down 17.2% from $0.8 million the previous year.
Is Brainstorm Cell Therapeutics profitable?
No. Brainstorm Cell Therapeutics reported a net loss of $10.3 million in fiscal 2025, a net profit margin of −1,466.1%; its operating margin was −1,415.8%.
How much does Brainstorm Cell Therapeutics spend on research and development?
Brainstorm Cell Therapeutics spent $4.2 million on research and development in fiscal 2025, 593.9% of revenue.
What are Brainstorm Cell Therapeutics's earnings per share?
Brainstorm Cell Therapeutics earned $-1.11 per diluted share in fiscal 2025, compared with $-3.12 a year earlier.
When does Brainstorm Cell Therapeutics's fiscal year end?
Brainstorm Cell Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.